Although Hispanics and NHW had a similar likelihood of being on biologics (including TNF inhibitors, ustekinumab, and vedolizumab), we found that NHWs were more likely to be on dual therapy with a biologic and an immunomodulator and were more likely to have ever been placed on steroids for IBD. This evidence concerns the gene TNF and inflammatory bowel disease.